Moderna Up 109% YTD: Cramer Calls It Investable—Is It a Buy on the Dip?
Jim Cramer’s bullish pivot comes as Moderna stock pulls back from its 109% YTD gain, raising the question: does the dip offer a compelling entry for investors?
Finance entity
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention COVID-19 Vaccine, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Finance story that mention Cytomegalovirus (CMV) candidate, all published on July 21, 2026.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. Of the tracked stories, 1 of 1 also mention COVID-19 Vaccine, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Finance story that mention Cytomegalovirus (CMV) candidate, all published on July 21, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cytomegalovirus (CMV) candidate. Shared-story counts are live from our verified record — not editorial picks.
Jim Cramer’s bullish pivot comes as Moderna stock pulls back from its 109% YTD gain, raising the question: does the dip offer a compelling entry for investors?
Cytomegalovirus (CMV) candidate is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.